CL2008000202A1 - Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. - Google Patents

Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.

Info

Publication number
CL2008000202A1
CL2008000202A1 CL2008000202A CL2008000202A CL2008000202A1 CL 2008000202 A1 CL2008000202 A1 CL 2008000202A1 CL 2008000202 A CL2008000202 A CL 2008000202A CL 2008000202 A CL2008000202 A CL 2008000202A CL 2008000202 A1 CL2008000202 A1 CL 2008000202A1
Authority
CL
Chile
Prior art keywords
acetamide
aryl
useful
pharmaceutical composition
pain
Prior art date
Application number
CL2008000202A
Other languages
English (en)
Inventor
Hideharu Uchida
Shinichi Ogawa
Nuneyoshi Makabe
Yoshitaka Maeda
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of CL2008000202A1 publication Critical patent/CL2008000202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos derivados de n-aril-acetamida; composición farmacéutica, útiles para prevenir o tratar el dolor.
CL2008000202A 2007-01-24 2008-01-24 Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. CL2008000202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007014372 2007-01-24

Publications (1)

Publication Number Publication Date
CL2008000202A1 true CL2008000202A1 (es) 2009-10-02

Family

ID=39644589

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008000202A CL2008000202A1 (es) 2007-01-24 2008-01-24 Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.

Country Status (14)

Country Link
EP (1) EP2128157A4 (es)
JP (1) JPWO2008091021A1 (es)
KR (1) KR20090107068A (es)
CN (1) CN101589038A (es)
AR (1) AR065014A1 (es)
AU (1) AU2008208224A1 (es)
CA (1) CA2676020A1 (es)
CL (1) CL2008000202A1 (es)
CO (1) CO6210825A2 (es)
MX (1) MX2009007954A (es)
PA (1) PA8766901A1 (es)
PE (1) PE20081692A1 (es)
TW (1) TW200902002A (es)
WO (1) WO2008091021A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908753B1 (en) 2005-07-22 2014-12-17 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
CA2647256A1 (en) * 2006-04-18 2007-10-25 Abbott Laboratories Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
JP2011201776A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
US8492568B2 (en) 2008-06-17 2013-07-23 Glenmark Pharamceuticals S.A. Chromane derivatives as TRPV3 modulators
JP2011201777A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
JP2011201778A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ｐ−置換アリールアセトアミドを有するヘテロシクリデン誘導体
JP5934778B2 (ja) 2011-03-25 2016-06-15 アッヴィ・インコーポレイテッド Ｔｒｐｖ１拮抗薬
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
EP4019485A4 (en) * 2019-08-23 2022-10-26 Mochida Pharmaceutical Co., Ltd. METHOD FOR THE PRODUCTION OF HETEROCYCLIDENE ACETAMIDE DERIVATIVES
KR102334947B1 (ko) * 2020-04-22 2021-12-06 주식회사 제이맥켐 Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309621D0 (en) 1993-05-11 1993-06-23 Wellcome Found Amide derivatives and their therapeutic use
CN1040748C (zh) 1993-08-26 1998-11-18 山之内制药株式会社 苯并吖庚因衍生物及其药物组合物和中间体
DE19620170A1 (de) 1996-05-20 1997-11-27 Wolfgang Prof Dr Dr Pfleiderer Nucleosid-Derivate mit photolabilen Schutzgruppen
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
AU1309701A (en) 1999-11-15 2001-05-30 Nissan Chemical Industries Ltd. Hydrazone compounds and pesticides
US6120964A (en) 1999-12-15 2000-09-19 Eastman Kodak Company 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers
MXPA04004501A (es) 2001-11-16 2004-08-11 Yamanouchi Pharma Co Ltd Derivados de 4-4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sales de los mismos.
JP2005518371A (ja) * 2001-12-10 2005-06-23 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療に於けるこれらの使用
EP1480954B1 (en) * 2002-02-15 2008-12-03 Glaxo Group Limited Vanilloid receptor modulators
ATE355287T1 (de) * 2002-05-29 2006-03-15 Amgen Inc 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
EP1575918A2 (en) 2002-12-19 2005-09-21 Neurogen Corporation Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
CA2514940A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid vr1 receptor
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
JP4400566B2 (ja) 2003-06-12 2010-01-20 アステラス製薬株式会社 ベンズアミド誘導体又はその塩
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
SI2017276T1 (sl) 2003-09-22 2011-05-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
BRPI0415179A (pt) 2003-10-07 2006-11-28 Renovis Inc derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP2007523888A (ja) 2003-11-08 2007-08-23 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−キノリニル尿素誘導体
AU2005206561A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005095329A1 (en) 2004-03-31 2005-10-13 Pfizer Japan Inc. Substituted benzamide compounds as vr1 receptor antagonists
AU2005260821B2 (en) 2004-07-15 2010-02-18 Japan Tobacco Inc. Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor
US20080070946A1 (en) 2004-10-08 2008-03-20 Astrazeneca Ab Hydroxymethylbenzothiazoles Amides
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
JP2007014372A (ja) 2005-07-05 2007-01-25 Kariya Mokuzai Kogyo Kk 椅子
EP1908753B1 (en) * 2005-07-22 2014-12-17 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative

Also Published As

Publication number Publication date
KR20090107068A (ko) 2009-10-12
PA8766901A1 (es) 2009-06-23
CN101589038A (zh) 2009-11-25
EP2128157A1 (en) 2009-12-02
PE20081692A1 (es) 2008-12-18
JPWO2008091021A1 (ja) 2010-05-20
EP2128157A4 (en) 2010-03-17
CO6210825A2 (es) 2010-10-20
WO2008091021A1 (ja) 2008-07-31
TW200902002A (en) 2009-01-16
CA2676020A1 (en) 2008-07-31
MX2009007954A (es) 2009-08-07
AU2008208224A1 (en) 2008-07-31
AR065014A1 (es) 2009-05-13

Similar Documents

Publication Publication Date Title
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
ECSP088752A (es) Formulaciones para administración parenteral de compuestos y sus usos
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos